Menu Search
Equities

Curatis Holding AG

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0QNS:LSE

Curatis Holding AG

Actions
  • Price (CHF)16.25
  • Today's Change0.00 / 0.00%
  • Shares traded300.00
  • 1 Year change--
  • Beta2.4736
Data delayed at least 20 minutes, as of Feb 10 2026 15:38 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Curatis Holding AG formerly Kinarus Therapeutics Holding AG is a Switzerland-based company that operates in specialty pharmaceutical and therapeutic drug industry. The Company conducts its work within clinical-stage area and focuses on the acquisition, development and commercialisation of medicines for the prevention, diagnosis and treatment of diseases. This is done by distributing specialty pharmaceuticals throughout Switzerland, with aims to expanded to larger European markets such as Germany, France, United Kingdom as well as Italy. The drugs and treatments produced are primarily developed in order to treat rare diseases, often referred to as orphan diseases, which receive little funding, relative to more common disorders.

  • Revenue in CHF (TTM)10.16m
  • Net income in CHF-1.64m
  • Incorporated1997
  • Employees15.00
  • Location
    Curatis Holding AGWeierweg 7LIESTAL 4057SwitzerlandCHE
  • Phone+41 619278777
  • Fax+41 619278775
  • Websitehttps://curatis.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.